Onco Wiki / Biomarcador

EBV estado (EBER- ISH no tecido tumoral)

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

IDBIO-EBV-STATUS
TipoBiomarcador
Alegais
EBEREBVEstado do EBVEBV статус (EBER-ISH на тканині)Vírus Epstein-Barr
Estadoreviewed 2026-04-25 | pending_clinical_signoff
DoençasDIS-AITL DIS-GASTRIC
FontesSRC-NCCN-BCELL-2025

Fatos de biomarcadores

Tipo de biomarcadorviral_load
Medição
MétodoEBER (EBV-encoded RNA) in-situ hybridization on FFPE tissue. Serum EBV-DNA quantitative for systemic involvement
Unidadescategorical (positive | negative); EBV-DNA copies/mL for serum
Biomarcadores relacionadosNenhuma declaração

Notas

Cross-disease etiologic + therapeutic significance: - **Endemic Burkitt** (equatorial Africa): EBV+ in ~95% - **Sporadic Burkitt** (Western): EBV+ in ~15% - **Classical Hodgkin**: EBV+ in ~30-40% (mixed cellularity highest) - **Post-transplant LPD (PTLD)**: EBV-driven; rituximab + reduce immunosuppression often curative - **HIV-associated DLBCL / plasmablastic / primary effusion**: EBV+ common - **NK/T nasal-type lymphoma**: EBV+ universally - **AITL microenvironment**: EBV+ B-cells frequent - **EBV+ DLBCL of elderly** (WHO 5th-ed entity): defined by EBV+ Drives different treatment context: - PTLD → reduce immunosuppression + rituximab - HIV-associated → cART + standard regimen - EBV+ HL has same regimen but PD-1 blockade emerging response differential Currently informational in our KB; not algorithm-driving for treatment selection but documented for clinical context.

Usado por

Relevância terapêutica

Biomarcador

Sinal de alerta